contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-will-provide-ai-solutions-for-breast-and-prostate-cancer-diagnostics-for-fimlab-laboratories

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Juha Kinnunen

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.

Aiforia Technologies

Fimlab Laboratories Ltd, Finland's largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.  

Translation: Original comment published in Finnish on 08/02/2024 at 7:26 am EEST
Fimlab Laboratories Ltd, Finland&apos;s largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.&#xa0; The value of the first order is approximately EUR 300,000 for the first year, which is some 7% of our 2024 revenue forecast. The order and the concrete launch of the collaboration again support Aiforia&#x2019;s strong growth prospects.&#xa0; 
<h2>Based on an earlier framework agreement</h2>
Earlier in May, Aiforia <a href="https://www.inderes.se/releases/aiforia-wins-a-framework-agreement-to-provide-ai-solutions-for-fimlab-laboratories-in-finland">announced</a> the signing of a framework agreement, in which it was selected as one of the suppliers of AI solutions for Fimlab to support pathology diagnostics.. The three best suppliers were chosen for AI models for nine applications and a development platform for AI models. Aiforia was qualified as one of the suppliers for eight applications and the development platform. The main owners of Fimlab are the wellbeing services counties of Pirkanmaa, Kanta-H&#xe4;me, Central Finland, P&#xe4;ij&#xe4;t-H&#xe4;me and Ostrobothnia. 
<h2>The contract supports our growth forecasts</h2>
AI solutions for breast and prostate cancer, covering three applications, are Aiforia&#x2019;s first actual order under this multi-annual framework agreement. The value of this first order for Aiforia is approximately EUR 300,000 for the first year, which is around 7% of our 2024 revenue forecast. The size of the agreement was not yet commented on in May and its size class is already larger in the initiation stage than our previous interpretation. This means that this is a very significant order for the company, and there is significantly more potential in this collaboration. Our forecasts assume continuous significant customer gains for the company, so the impact of the release is more supportive of our forecasts than causing pressure to change them.

Inderes

Aiforia will provide AI solutions for breast and prostate cancer diagnostics for Fimlab Laboratories

	2023	24e	25e
Revenue	2.4	4.3	8.1
growth-%	49.3 %	80.1 %	88.4 %
EBIT (adj.)	-12.9	-11.5	-10.1
EBIT-% (adj.)	-537.1 %	-266.2 %	-124.3 %
EPS (adj.)	-0.50	-0.41	-0.36
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia will provide AI solutions for breast and prostate cancer diagnostics for Fimlab Laboratories

Based on an earlier framework agreement

The contract supports our growth forecasts

Aiforia Technologies

Key Estimate Figures29.05.2024

Privacy preferences